Elliott Management Takes Significant Stake in Dexcom, Pushes for Board Refresh
Dexcom gains Elliott stake; will add board members and restructure, betting on CGM growth; shares rose 6%.
Dexcom gains Elliott stake; will add board members and restructure, betting on CGM growth; shares rose 6%.
FDA pauses Aardvark’s PWS drug trials over safety concerns; studies stop, shares fall, talks with FDA ongoing.
FDA gave Fast Track to INmune Bio’s XPro for early Alzheimer’s, speeding trials of a drug targeting brain inflammation.
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.
WW International rose after Galloway Capital built 8.42% stake, saying company is undervalued despite debt issues.